<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00595959</url>
  </required_header>
  <id_info>
    <org_study_id>9000-0001-03 CELLO</org_study_id>
    <nct_id>NCT00595959</nct_id>
  </id_info>
  <brief_title>CELLO - CLiRpath® Excimer Laser System to Enlarge Lumen Openings</brief_title>
  <acronym>CELLO</acronym>
  <official_title>CLiRpath® Excimer Laser System to Enlarge Lumen Openings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectranetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectranetics Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of the CLiRpath®
      Photoablation Atherectomy System consisting of the Bias Sheath guiding catheter, in
      combination with the available CLiRpath® Excimer Laser Catheters ≤ 2.0 mm, to create larger
      lumens for treatment within the superficial femoral and popliteal arteries above the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laser Success</measure>
    <time_frame>Measured at time of procedure</time_frame>
    <description>The primary efficacy endpoint is laser success, defined as achieving &gt;/= 20% average reduction in the percent (%) diameter stenosis, post-laser and prior to adjunctive therapy, based on angiographic core laboratory assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>From discharge through the 6 month follow-up</time_frame>
    <description>The primary safety endpoint is the occurrence of major adverse events defined as clinical perforation, major dissection requiring surgery, major amputation, cerebrovascular accidents (CVA), myocardial infarction, and death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>measured at time of procedure</time_frame>
    <description>Acute procedural success, defined as achievement of &lt;/= 30% final residual stenosis, as visually assessed by angiography after all adjunctive treatment(s) deemed necessary by the treating physician. Measures % of patients who achieved a final residual stenosis of &lt;/=30%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum and Maximum Lumen Diameters</measure>
    <time_frame>measured at time of procedure</time_frame>
    <description>Minimum and maximum lumen diameters immediately after treatment with the CLiRpath® Photoablation Atherectomy System as determined by Intravascular Ultrasound (IVUS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>measured post discharge thorugh 12 Months follow-up</time_frame>
    <description>Clinical success, defined as primary patency (≤ 50% stenosis at the treatment site), as assessed by duplex Doppler ultrasound at 30 days, six (6) months and 12 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Primary Patency</measure>
    <time_frame>Through 12 Months</time_frame>
    <description>Incidence of freedom from assisted primary patency at 30 days, six (6) and 12 months post-procedure, defined as a re-intervention of a stenosis (patent vessel) at the treatment site to prevent reocclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Secondary Patency</measure>
    <time_frame>Through 12 Month</time_frame>
    <description>Incidence of freedom from assisted secondary patency at 30 days, six (6) and 12 months post-procedure, defined as a re-intervention of a reocclusion (non-patent vessel) at the treatment site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With &gt;50% Stenosis Measured by Duplex Ultrasound</measure>
    <time_frame>Through 12 Month</time_frame>
    <description>Percentage of patients with &gt;50% stenosis at each follow-up (30 days, six months, and 12 months post-procedure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford Classification</measure>
    <time_frame>Through 12 Months</time_frame>
    <description>Rutherford Classification at 30 days, six (6) and 12 months post-procedure. Physician assessed based on ankle pressures and treadmill testing. Rutherford scale: 0=best, 6=worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through 12 Months</time_frame>
    <description>Adverse events during procedure and prior to release from the hospital, at 30 days, six (6) months, and 12 months post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric Plaque Reduction</measure>
    <time_frame>measured at time of procedure</time_frame>
    <description>Volumetric plaque reduction immediately after treatment with the CLiRpath® Photoablation Atherectomy System as determined by IVUS. Actual volume of plaque present is presented for each measurement point.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Laser Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLiRpath Photoablation Atherectomy System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CLiRpath Photoablation System</intervention_name>
    <description>Use of CLiRpath Laser Catheter to improve vessel lumen diameter.</description>
    <arm_group_label>Laser Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria

          1. Peripheral vascular disease Rutherford Classification 1, 2, or 3;

          2. Eligible for revascularization of native vessel (PTA or bypass);

          3. Willing and able to comply with the specified evaluations during hospitalization and
             all required follow-up examinations;

          4. Written informed consent given before execution of study procedures; and

          5. Age &gt; 18 and ≤ 85 years.

        Angiographic Inclusion Criteria

          1. Reference vessel diameter &gt;/= 4.0 mm and ≤ 7.0 mm as determined by physician visual
             angiographic assessment of the most normally appearing vessel segment within 10 mm
             proximal AND 10 mm distal to the target segment.

          2. Stenosis within the SFA and/or popliteal artery above the knee of &gt;/= 70% and &lt;/= 100%
             DS (occlusion), as determined by visual angiographic assessment by the investigator at
             the time of the procedure and documented by angiography in at least two (2) orthogonal
             views.

          3. At least 1.0 cm of visible SFA stump beyond the origin of the profunda artery.

          4. Total lesion length &gt;/= 1.0 cm and ≤ 15.0 cm as determined by visual angiographic
             assessment at the time of the procedure, separate multiple lesions can be combined as
             two separate treatment areas as long as the sum total of all lesion lengths and/or
             treatment areas does not exceed 1.0 cm to 15.0 cm.

          5. Patency (&lt; 50% DS) of at least one (1) infrapopliteal artery in continuity with the
             native femoropopliteal artery.

        Exclusion Criteria:

        General Exclusion Criteria

          1. Contraindication to intravenous contrast material, heparin, aspirin or other
             medications required for a percutaneous interventional procedure;

          2. Known bleeding or hyper-coagulation disorder;

          3. Serum creatinine &gt; 2.0 mg/dL;

          4. Uncompensated congestive heart failure;

          5. Current enrollment in any investigational study wherein patient participation has not
             been completed;

          6. Prior enrollment in this study;

          7. Suspected or confirmed pregnancy;

          8. Any patient, who in the opinion of the investigator, would not be a good candidate for
             enrollment;

          9. Myocardial infarction within 60 days; and

         10. CVA/TIA within 60 days. Angiographic Exclusion Criteria

        1.

          1. Subintimal guidewire placement following pilot channel creation through a stenosis or
             occlusion with any excimer laser catheter, as visualized with IVUS;

          2. Calcification likely to prevent the passage of the excimer laser catheter or CLiRpath®
             Photoablation Atherectomy system;

          3. Ipsilateral and/or contralateral iliac stenosis &gt;/= 50% DS that is not treated prior
             to enrollment in this study;

          4. Ipsilateral and/or contralateral iliac treatment of a stenosis prior to enrollment
             with final residual stenosis &gt;/= 30%, as determined in at least two (2) orthogonal
             views and documented by angiography;

          5. Iliac treatment prior to enrollment where a perforation occurred requiring a covered
             stent, blood transfusion, or surgery for treatment of the perforation;

          6. Identification of any lesion above the knee and/or below the knee in the treated leg
             (ipsilateral) that will require preplanned or predicted treatment within six (6)
             months after enrollment and prior to the completion of the six (6) month follow-up,
             including the iliac artery, the common femoral artery, the peroneal, anterior tibial,
             or posterior tibial arteries, or any area from the iliacs to the foot outside of the
             treatment area;

          7. Lesions proximal and distal to the treatment site that are &gt;/= 50% DS at time of
             enrollment;

          8. Contralateral leg disease that requires treatment within the next 30 days and prior to
             completion of the 30 day follow-up;

          9. Cardiovascular surgical or cardiovascular interventional procedures (including, but
             not limited to, aortic, renal, cardiac, carotid, femoro-popliteal, and below the knee)
             within 30 days prior to enrollment in this study;

         10. Planned or predicted cardiovascular surgical or interventional procedures outside of
             the ipsilateral leg (including, but not limited to aortic, renal, cardiac, carotid,
             contralateral femoro-popliteal, and contralateral below the knee) within 30 days after
             entry into this study, and prior to completion of the 30-day follow-up; and

         11. Perforation or dissection of grade &quot;C&quot; or greater seen during or after the creation of
             the pilot channel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M Rasmussen</last_name>
    <role>Study Director</role>
    <affiliation>Spectranetics Corp.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajesh Dave, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pinnacle Health Hospital, Central Pennsylvania Research Foundation</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <results_first_submitted>February 23, 2009</results_first_submitted>
  <results_first_submitted_qc>April 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2009</results_first_posted>
  <last_update_submitted>June 13, 2011</last_update_submitted>
  <last_update_submitted_qc>June 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Rajesh M. Dave, M.D.</name_title>
    <organization>Pinnacle Health Hospital, Central Pennsylvania Research Foundation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from investigator patient referral base. Recruitment occurred between November 2006 and March 2007</recruitment_details>
      <pre_assignment_details>Patients were screened for inclusion/exclusion criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Laser Treatment</title>
          <description>CLiRpath Photoablation Atherectomy System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Laser Treatment</title>
          <description>CLiRpath Photoablation Atherectomy System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Laser Success</title>
        <description>The primary efficacy endpoint is laser success, defined as achieving &gt;/= 20% average reduction in the percent (%) diameter stenosis, post-laser and prior to adjunctive therapy, based on angiographic core laboratory assessment.</description>
        <time_frame>Measured at time of procedure</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Laser Success</title>
          <description>The primary efficacy endpoint is laser success, defined as achieving &gt;/= 20% average reduction in the percent (%) diameter stenosis, post-laser and prior to adjunctive therapy, based on angiographic core laboratory assessment.</description>
          <population>Per protocol</population>
          <units>percent reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparing to an expected value of 20% reduction from initial to post-laser</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>No adjustments</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Events</title>
        <description>The primary safety endpoint is the occurrence of major adverse events defined as clinical perforation, major dissection requiring surgery, major amputation, cerebrovascular accidents (CVA), myocardial infarction, and death.</description>
        <time_frame>From discharge through the 6 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Events</title>
          <description>The primary safety endpoint is the occurrence of major adverse events defined as clinical perforation, major dissection requiring surgery, major amputation, cerebrovascular accidents (CVA), myocardial infarction, and death.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Acute procedural success, defined as achievement of &lt;/= 30% final residual stenosis, as visually assessed by angiography after all adjunctive treatment(s) deemed necessary by the treating physician. Measures % of patients who achieved a final residual stenosis of &lt;/=30%.</description>
        <time_frame>measured at time of procedure</time_frame>
        <population>Per protocol. All enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Acute procedural success, defined as achievement of &lt;/= 30% final residual stenosis, as visually assessed by angiography after all adjunctive treatment(s) deemed necessary by the treating physician. Measures % of patients who achieved a final residual stenosis of &lt;/=30%.</description>
          <population>Per protocol. All enrolled patients</population>
          <units>percent with &lt;/=30% RS</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum and Maximum Lumen Diameters</title>
        <description>Minimum and maximum lumen diameters immediately after treatment with the CLiRpath® Photoablation Atherectomy System as determined by Intravascular Ultrasound (IVUS).</description>
        <time_frame>measured at time of procedure</time_frame>
        <population>Analysis per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum and Maximum Lumen Diameters</title>
          <description>Minimum and maximum lumen diameters immediately after treatment with the CLiRpath® Photoablation Atherectomy System as determined by Intravascular Ultrasound (IVUS).</description>
          <population>Analysis per protocol</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post pilot channel max lumen diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Turbo-Booster max lumen diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post pilot channel min lumen diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Turbo-Booster min lumen diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>Clinical success, defined as primary patency (≤ 50% stenosis at the treatment site), as assessed by duplex Doppler ultrasound at 30 days, six (6) months and 12 months post-procedure</description>
        <time_frame>measured post discharge thorugh 12 Months follow-up</time_frame>
        <population>65 patients at 30 days; 59 at 6 months; 46 at 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>Clinical success, defined as primary patency (≤ 50% stenosis at the treatment site), as assessed by duplex Doppler ultrasound at 30 days, six (6) months and 12 months post-procedure</description>
          <population>65 patients at 30 days; 59 at 6 months; 46 at 12 months</population>
          <units>percent of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days; n=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months; n=59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months; n=46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Primary Patency</title>
        <description>Incidence of freedom from assisted primary patency at 30 days, six (6) and 12 months post-procedure, defined as a re-intervention of a stenosis (patent vessel) at the treatment site to prevent reocclusion</description>
        <time_frame>Through 12 Months</time_frame>
        <population>65 at 30 days; 64 at 6 months; 63 at 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Assisted Primary Patency</title>
          <description>Incidence of freedom from assisted primary patency at 30 days, six (6) and 12 months post-procedure, defined as a re-intervention of a stenosis (patent vessel) at the treatment site to prevent reocclusion</description>
          <population>65 at 30 days; 64 at 6 months; 63 at 12 months</population>
          <units>% pts free from assisted primary patency</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days; n=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months; n=64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months; n=63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Secondary Patency</title>
        <description>Incidence of freedom from assisted secondary patency at 30 days, six (6) and 12 months post-procedure, defined as a re-intervention of a reocclusion (non-patent vessel) at the treatment site</description>
        <time_frame>Through 12 Month</time_frame>
        <population>65 at 30 days; 64 at 6 months; 63 at 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Assisted Secondary Patency</title>
          <description>Incidence of freedom from assisted secondary patency at 30 days, six (6) and 12 months post-procedure, defined as a re-intervention of a reocclusion (non-patent vessel) at the treatment site</description>
          <population>65 at 30 days; 64 at 6 months; 63 at 12 months</population>
          <units>% pts free from secondary patency</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days; n=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months; n=64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months; n=63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With &gt;50% Stenosis Measured by Duplex Ultrasound</title>
        <description>Percentage of patients with &gt;50% stenosis at each follow-up (30 days, six months, and 12 months post-procedure).</description>
        <time_frame>Through 12 Month</time_frame>
        <population>per protocol; 65 patients at 30 days; 59 at 6 months and 46 at 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With &gt;50% Stenosis Measured by Duplex Ultrasound</title>
          <description>Percentage of patients with &gt;50% stenosis at each follow-up (30 days, six months, and 12 months post-procedure).</description>
          <population>per protocol; 65 patients at 30 days; 59 at 6 months and 46 at 12 months</population>
          <units>percent of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days; n=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months; n=59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months; n=46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Walking Impairment Questionare (WIQ)</title>
        <description>Measures difficulty in walking before and after treatment. Defined by comparing the responses to a WIQ at pre-treatment with the responses at 30 days, six (6) months and 12 months post-procedure. Higher score is better (scale 0-100).</description>
        <time_frame>measured at each follow-up period</time_frame>
        <population>65 patients at baseline and 30 days; 64 at 6 mo; 63 at 12 mo</population>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Impairment Questionare (WIQ)</title>
          <description>Measures difficulty in walking before and after treatment. Defined by comparing the responses to a WIQ at pre-treatment with the responses at 30 days, six (6) months and 12 months post-procedure. Higher score is better (scale 0-100).</description>
          <population>65 patients at baseline and 30 days; 64 at 6 mo; 63 at 12 mo</population>
          <units>units on a scale 0-100</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline; n=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days; n=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months; n=64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months; n=63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rutherford Classification</title>
        <description>Rutherford Classification at 30 days, six (6) and 12 months post-procedure. Physician assessed based on ankle pressures and treadmill testing. Rutherford scale: 0=best, 6=worst</description>
        <time_frame>Through 12 Months</time_frame>
        <population>63 at baseline; 62 at 30days and 6 months; 63 at 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Rutherford Classification</title>
          <description>Rutherford Classification at 30 days, six (6) and 12 months post-procedure. Physician assessed based on ankle pressures and treadmill testing. Rutherford scale: 0=best, 6=worst</description>
          <population>63 at baseline; 62 at 30days and 6 months; 63 at 12 months</population>
          <units>units on a scale of 0-6</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline; n=63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days; n=62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months; n=62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months; n=63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Adverse events during procedure and prior to release from the hospital, at 30 days, six (6) months, and 12 months post-procedure.</description>
        <time_frame>Through 12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Adverse events during procedure and prior to release from the hospital, at 30 days, six (6) months, and 12 months post-procedure.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Procedure/24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volumetric Plaque Reduction</title>
        <description>Volumetric plaque reduction immediately after treatment with the CLiRpath® Photoablation Atherectomy System as determined by IVUS. Actual volume of plaque present is presented for each measurement point.</description>
        <time_frame>measured at time of procedure</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>CLiRpath Photoablation Atherectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Volumetric Plaque Reduction</title>
          <description>Volumetric plaque reduction immediately after treatment with the CLiRpath® Photoablation Atherectomy System as determined by IVUS. Actual volume of plaque present is presented for each measurement point.</description>
          <population>Per protocol</population>
          <units>millimeters cubed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post pilot channel plaque volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.8" spread="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Turbo Booster plaque volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.8" spread="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Laser Treatment</title>
          <description>CLiRpath Photoablation Atherectomy System</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass graft</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neck, back and shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sternum infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Right renal artery and non-treated leg stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vessel occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hematoma at access site</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Occlusion to treated leg other than at lesion site</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Non-randomized study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas M. Rasmussen V.P. Clinical Affairs</name_or_title>
      <organization>Spectranetics Inc</organization>
      <phone>719-447-2471</phone>
      <email>thomas.rasmussen@spnc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

